Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

Phase 3 Recruiting 500 enrolled Imunon

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a randomized, adaptive, open label, multicenter trial to evaluate the safety and efficacy of intraperitoneal (IP) IMNN-001 plus chemotherapy compared to chemotherapy alone.

Timeline

Start: 2025-07-09
Primary completion: 2032-10-31
Completion: 2032-10-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	IMNN-001	Other / unclassified	100 mg/m2	Other
Background	Carboplatin	Small molecule	6 unknown	Intravenous
Background	Niraparib	Small molecule	200 mg	Oral
Background	Niraparib	Small molecule	300 mg	Oral
Background	Olaparib	Small molecule	300 mg	Oral
Background	Paclitaxel	Small molecule	175 mg/m2	Intravenous

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

Summary

Timeline

Drugs

Indications